Sarepta Advances Precision Genetic Therapies Toward Full FDA Approval: AMONDYS 45 and VYONDYS 53 Seek Traditional Approval Status

Sarepta Therapeutics has announced a significant regulatory milestone in its efforts to secure permanent FDA approval for two breakthrough Duchenne muscular dystrophy (DMD) treatments. As reported by BusinesWire.com, the company…

Continue Reading Sarepta Advances Precision Genetic Therapies Toward Full FDA Approval: AMONDYS 45 and VYONDYS 53 Seek Traditional Approval Status

Long-Term Study Shows Givinostat’s Promise for Duchenne Muscular Dystrophy Treatment

ITF Therapeutics has announced the publication of encouraging long-term data supporting the efficacy and safety of givinostat as a treatment for Duchenne muscular dystrophy (DMD), according to a recent article…

Continue Reading Long-Term Study Shows Givinostat’s Promise for Duchenne Muscular Dystrophy Treatment
A Parent’s Take on Marriage While Having a Child with Duchenne Muscular Dystrophy
source: pixabay.com

A Parent’s Take on Marriage While Having a Child with Duchenne Muscular Dystrophy

  Betty Vertin recently wrote an article discussing her experience as a parent of a child with Duchenne muscular dystrophy. She shares the lessons she has learned in order to…

Continue Reading A Parent’s Take on Marriage While Having a Child with Duchenne Muscular Dystrophy
First Patient Dosed in Phase 3 Study of Experimental Idiopathic Pulmonary Fibrosis Drug
source: pixabay.com

First Patient Dosed in Phase 3 Study of Experimental Idiopathic Pulmonary Fibrosis Drug

According to a press release from the San Francisco-based FibroGen, Inc., the first patient has been dosed in the Company's phase 3 clinical study of the experimental drug pamrevlumab for…

Continue Reading First Patient Dosed in Phase 3 Study of Experimental Idiopathic Pulmonary Fibrosis Drug